← Leaderboards
Ian S Grimm
University Of North Carolina Chapel Hill
$1,559,955
Attributed
$1,559,955
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,559,955 · 1
By mechanism
M01$1,559,955 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- John B Buse$71,388,050
- Charles Michael Van Der Horst$17,688,631
- Douglas A Drossman$8,090,089
- Eugene P Orringer$33,565,484
- Kirkwood F Adams$4,990,072
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchDrug Screening /EvaluationHepatitis BHepatitis B Virus GroupHuman SubjectHuman Therapy EvaluationLamivudineLiver Disorder ChemotherapyRelapse /RecurrenceSerology /SerodiagnosisVirus Dna
Grant awards (7)
EPIDEMIOLOGY OF DURATION RESPONSE TO LAMIVUDINE IN HEPATITIS B$190,747
M01 · FY2002 · RR
EPIDEMIOLOGY OF DURATION RESPONSE TO LAMIVUDINE IN HEPATITIS B$294,555
M01 · FY2001 · RR
EPIDEMIOLOGY OF DURATION RESPONSE TO LAMIVUDINE IN HEPATITIS B$190,747
M01 · FY2001 · RR
EPIDEMIOLOGY OF DURATION RESPONSE TO LAMIVUDINE IN HEPATITIS B$294,555
M01 · FY2000 · RR
EPIDEMIOLOGY OF DURATION RESPONSE TO LAMIVUDINE IN HEPATITIS B$294,555
M01 · FY2000 · RR
EPIDEMIOLOGY OF DURATION RESPONSE TO LAMIVUDINE IN HEPATITIS B$294,555
M01 · FY2000 · RR
EPIDEMIOLOGY OF DURATION RESPONSE TO LAMIVUDINE IN HEPATITIS B$241
M01 · FY2000 · RR